NA
MRNA icon

NewEdge Advisors’s Moderna MRNA Stock Holding History

NewEdge Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306K Buy
4,364
+2,947
+208% +$152K ﹤0.01% 2471
2026
Q1 		$72K Buy
1,417
+401
+39% +$18.7K ﹤0.01% 2845
2025
Q4 		$30K Sell
1,016
-14,459
-93% -$393K ﹤0.01% 3125
2025
Q3 		$400K Sell
15,475
-65
-0.4% -$1.81K ﹤0.01% 1977
2025
Q2 		$429K Buy
15,540
+3,965
+34% +$104K ﹤0.01% 1788
2025
Q1 		$328K Buy
11,575
+10,185
+733% +$361K ﹤0.01% 1836
2024
Q4 		$57.8K Sell
1,390
-246
-15% -$11.8K ﹤0.01% 2473
2024
Q3 		$109K Sell
1,636
-6,137
-79% -$563K ﹤0.01% 2166
2024
Q2 		$923K Sell
7,773
-5,773
-43% -$731K 0.01% 1110
2024
Q1 		$1.44M Buy
13,546
+1,228
+10% +$124K 0.01% 820
2023
Q4 		$1.25M Buy
12,318
+6,172
+100% +$519K 0.01% 842
2023
Q3 		$635K Sell
6,146
-545
-8% -$60.8K 0.01% 1068
2023
Q2 		$813K Sell
6,691
-2,179
-25% -$291K 0.01% 960
2023
Q1 		$1.27M Buy
8,870
+576
+7% +$95K 0.02% 695
2022
Q4 		$1.04M Buy
8,294
+1,530
+23% +$250K 0.03% 497
2022
Q3 		$800K Sell
6,764
-1,237
-15% -$188K 0.01% 741
2022
Q2 		$1.14M Buy
+8,001
New +$1.14M 0.02% 622
2022
Q1 		– Sell
-8,724
Closed -$2.22M – 1445
2021
Q4 		$2.22M Sell
8,724
-4,234
-33% -$1.24M 0.03% 415
2021
Q3 		$4.99M Buy
12,958
+2,749
+27% +$1.01M 0.12% 171
2021
Q2 		$2.4M Buy
10,209
+7,889
+340% +$1.41M 0.06% 273
2021
Q1 		$304K Sell
2,320
-303
-12% -$43.9K 0.01% 806
2020
Q4 		$274K Sell
2,623
-3,980
-60% -$403K 0.01% 787
2020
Q3 		$467K Buy
+6,603
New +$460K 0.02% 595

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

NewEdge Advisors's MRNA Position: Q2 2026 in Review

NewEdge Advisors increased its Moderna (MRNA) stake by 208% in Q2 2026, buying an estimated $152K and bringing the position to 4,364 shares worth $306K. The position accounts for ﹤0.01% of the portfolio, ranked #2471.

NewEdge Advisors first reported a position in MRNA in Q3 2020 and has held it in 23 quarters since. The position peaked at $4.99M in Q3 2021. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • NewEdge Advisors held 4,364 shares of Moderna worth $306K as of Q2 2026.
  • NewEdge Advisors bought 2,947 Moderna shares in Q2 2026, an estimated $152K.
  • Moderna made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2471 holding.
  • NewEdge Advisors first reported a position in Moderna in Q3 2020 and has held it in 23 quarters since.
  • NewEdge Advisors's Moderna position peaked at $4.99M in Q3 2021.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.